Breakthrough Treatments Reshaping the Glioblastoma Multiforme Market

ha aggiunto una foto Health

2025-03-27 07:32:14 -

Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer, with a poor prognosis and limited treatment options. The current glioblastoma multiforme survival rate remains dismal, with the majority of patients surviving only 12 to 18 months post-diagnosis. However, promising advancements in treatment, including the IMVAX clinical trial, are paving the way for...

0 Commenti 0 condivisioni 493 Views 0 Anteprima